JAMA Oncology Author Interviews

By JAMA Network

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.

  1. 1.
    Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer
    34:53
  2. 2.
    Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With NSCLC
    16:51
  3. 3.
    Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
    16:33
  4. 4.
    Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
    13:02
  5. 5.
    Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases
    19:06
  6. 6.
    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
    15:07
  7. 7.
    Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
    17:40
  8. 8.
    Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase
    29:38
  1. 9.
    Virtual Care Across a Tertiary Cancer Center During COVID-19
    23:44
  2. 10.
    Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases
    13:01
  3. 11.
    Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
    15:20
  4. 12.
    Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
    14:00
  5. 13.
    Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features
    23:13
  6. 14.
    Tailoring Intensity of Surveillance for Prostate Cancer Based on Prediction of Risk Stability
    18:57
  7. 15.
    Presence of ctDNA and CTCs After Chemotherapy and Recurrence of Triple-Negative Breast Cancer
    13:28
  8. 16.
    Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults
    24:17
  9. 17.
    Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
    15:24
  10. 18.
    Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
    11:37
  11. 19.
    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
    19:10
  12. 20.
    HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
    11:43
  13. 21.
    Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
    12:22
  14. 22.
    Association Between BMI and Overall Survival in Advanced Non–Small Cell Lung Cancer
    16:45
  15. 23.
    The Role of Maintenance Strategies in Metastatic Colorectal Cancer
    10:38
  16. 24.
    Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer
    12:23
  17. 25.
    Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
    14:40
  18. 26.
    Women’s Representation Among Lead Investigators of Clinical Trials in Oncology
    12:09
  19. 27.
    Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
    19:26
  20. 28.
    Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers
    15:50
  21. 29.
    Prognostic Potential of Circulating Tumor DNA Measurement in Nonmetastatic Colorectal Cancer
    14:02
  22. 30.
    Single-Fraction Stereotactic vs Multifraction Radiotherapy for Pain Relief in Patients With Nonspine Bone Metastases
    11:45
  23. 31.
    The Role of Disease Label in Patient Perceptions and Treatment Decisions in the Setting of Low-Risk Malignant Neoplasms
    13:51
  24. 32.
    Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer
    14:36
  25. 33.
    Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation
    14:52
  26. 34.
    Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal BMI
    14:49
  27. 35.
    Surgery vs Radiotherapy in the Management of Gleason Score 9-10 Prostate Cancer and the Risk of Mortality
    19:34
  28. 36.
    Analgesic Use and Risk of Ovarian Cancer in the Nurses’ Health Studies
    16:19
  29. 37.
    Hyperprogressive Disease in Patients With Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors
    15:21
  30. 38.
    Maintenance Treatment and Survival in Patients With Myeloma
    10:40
  31. 39.
    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening
    12:10
  32. 40.
    Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade
    9:44
  33. 41.
    Outcomes of Multiple-Gene Sequencing After Diagnosis of Breast Cancer
    7:38
  34. 42.
    Association of Colon Cancer Survival With ACS Guideline Adherence
    16:41
  35. 43.
    Standard vs Dose-Escalated Radiotherapy in Medium-Risk Prostate Cancer
    9:43
  36. 44.
    Atezolizumab Monotherapy for Patients With Metastatic Urothelial Cancer
    8:52
  37. 45.
    Dietary Inflammatory Potential and Risk of Colorectal Cancer in Men and Women
    10:46
  38. 46.
    Preoperative vs Postoperative CEA and Colon Cancer Outcome
    5:41
  39. 47.
    Critical Lessons From High-Value Oncology Practices
    11:18
  40. 48.
    Prophylactic Surgery for Stage IV Small Intestinal Neuroendocrine Tumors
    7:46
  41. 49.
    Trends in Adult Cancer–Related Emergency Department Utilization
    11:50
  42. 50.
    Prevalence of Cancer in Li-Fraumeni Syndrome Cohort
    8:28

Listen to JAMA Oncology Author Interviews now.

Listen to JAMA Oncology Author Interviews in full in the Spotify app